BioSpace News Archive

Suzhou Kintor Raises $44M for Novel Drug Portfolio

Suzhou Kintor Pharma raised $44M in a funding led by Shenzhen Green Pine Capital Partners.

January 15, 2018
·
1 min read
Biotech Bay

3 Biopharmas Worth Watching in 2018

Here are three biopharma stocks worth keeping an eye on.

January 15, 2018
·
2 min read
·
Mark Terry
BioMidwest

Boston Scientific, Medtronic Show Off Neuromodulation Devices Trial Data

The companies announced the data as an industry conference in Las Vegas.

January 15, 2018
·
1 min read
FDA

Following FDA Approval for PAD, Ra Medical Steps Up Hiring

Ra Medical only has five full-time salespeople on staff, but expects that to grow to 20 to 25 people later this year.

January 15, 2018
·
3 min read
·
Alex Keown
BioMidwest

The Top 6 Global Generic Drug Companies to Work For

Here’s a look at the top six generic drug companies to work for.

January 15, 2018
·
5 min read
·
Mark Terry
FDA

BD, Check-Points Win CE Mark for Next-Generation Resistant Bacteria Screening Test

The new test provides diagnostic results up to 10 times faster than traditional tests.

January 15, 2018
·
5 min read
Drug Development

Cingulate Therapeutics Presents New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting

Overall, researchers found that CTX-1301 delivered consistent tri-modal release of the dexmethylphenidate hydrochloride.

January 15, 2018
·
4 min read
Business

amcure Appoints Biotech Executive Heinz Schwer to its Board

January 15, 2018
·
2 min read
FDA

Teva Wins FDA Nod for TRISENOX (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia

The approval was based on a Priority Review by the FDA on data from published scientific literature and a review of Teva’s global safety database for arsenic trioxide.

January 15, 2018
·
11 min read
Business

Avacta Group Plc Announces Positive Outcome of Proof-of-Concept Study With Glythera and Follow-on Drug Development Partnership

Avacta Group plc is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug conjugates, has concluded successfully.

January 15, 2018
·
2 min read